Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Cedars Sinai has now started recruiting!

<< Previous

Bullboard Posts

Next >>

Post by scarlet1967on May 27, 2022 8:57am

233 Views

Post# 34711552

Cedars Sinai has now started recruiting!

Study No.
TH1902-CTR-001
Principal Investigator
Mita, Monica
Phase
I
Study Name
TH1902-CTR-001:A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic Cancer (IRB#1343)
Cancer Type
Anus; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Stomach; Thyroid; Urinary Bladder